Publications by authors named "A J J Lynch"

Background: As the primary cause of various preventable illnesses, smoking results in approximately five million premature deaths each year in the US and a multitude of adults living with serious illness. The majority of smokers know the health risks associated with smoking and intend to quit. However, quitting is very difficult partly because of insomnia and stress associated with it.

View Article and Find Full Text PDF

Here, we present a bioengineering approach to emulate the human bone marrow in vitro. Our developmentally inspired method uses self-organization of human hematopoietic stem and progenitor cells and vascular endothelial cells cultured in a three-dimensional microphysiological system to create vascularized, perfusable tissue constructs that resemble the hematopoietic vascular niche of the human marrow. The microengineered niche is capable of multilineage hematopoiesis and can generate functionally mature human myeloid cells that can intravasate into perfused blood vessels, providing a means to model the mobilization of innate immune cells from the marrow.

View Article and Find Full Text PDF
Article Synopsis
  • * A study reviewed 21 MLIV patients and conducted experiments on MLIV mouse models to understand kidney function, revealing that adult patients often have chronic kidney disease along with altered kidney functions and structure in the mice due to issues with endolysosomal function and autophagy.
  • * Results showed decreased kidney function, presence of fibrosis and inflammation in MLIV models, and impaired uptake of essential proteins, which highlights cellular and systemic dysfunction in the
View Article and Find Full Text PDF
Article Synopsis
  • Clinicians often prefer antiplatelet therapy over direct oral anticoagulants (DOACs) for atrial fibrillation due to concerns about higher risks of intracranial bleeding despite DOACs being more effective in preventing strokes.
  • The study aimed to compare the risks of intracranial and major hemorrhage between DOAC therapy and single-agent antiplatelet therapy using data from nine randomized clinical trials with nearly 45,500 participants.
  • Results showed no significant difference in the risk of intracranial hemorrhage between the two therapies; however, the analysis indicated variability in results among different DOACs, with rivarox
View Article and Find Full Text PDF